• Esther Rani Bulla
• Prabhu Kumar Turaka
• Tabitha Sharon M
• Kantamaneni Padmalatha

Human immunodeficiency virus (HIV) infection remains a global health challenge, with approximately 39 million people worldwide living with HIV in 2022. Transmission routes include illicit injections, blood transfusions, multiple sexual partners, and vertical transmission from mother to child. Without treatment, HIV can progress to acquired immunodeficiency syndrome (AIDS), leading to severe immunosuppression and increased susceptibility to opportunistic infections. The World Health Organization (WHO) recommends tenofovir (TDF) as a first-line antiretroviral treatment (ART) due to its efficacy and safety profile. This review article critically evaluates the safety and efficacy of TDF-based ART regimens compared to zidovudine (ZDV)-based regimens, focusing on cross-sectional research methodologies. Our analysis reveals that TDF-based regimens demonstrate superior efficacy, characterized by lower mortality rates, increased CD4 cell counts, and enhanced virologic suppression, particularly in treatment-naïve HIV patients. Moreover, TDF exhibits fewer harmful side effects compared to ZDV-based regimens, emphasizing its importance in HIV management. This review consolidates current evidence supporting TDF as a cornerstone of first-line ART regimens, offering insights into its role in improving patient outcomes and reducing the global burden of HIV/AIDS.

Human immunodeficiency virus (HIV), Acquired immune deficiency syndrome (AIDS), antiretroviral therapy (ART), Tenofovir (TDF), Zidovudine (ZDV), CD4 cells, side effects.

"A COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF FIRST-LINE ANTI-RETROVIRAL THERAPY REGIMENS: TENOFOVIR VERSUS ZIDOVUDINE IN MANAGING HUMAN IMMUNODEFICIENCY VIRUS AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 2, page no.d335-d343, February-2024, Available :http://www.jetir.org/papers/JETIR2402343.pdf

"A COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF FIRST-LINE ANTI-RETROVIRAL THERAPY REGIMENS: TENOFOVIR VERSUS ZIDOVUDINE IN MANAGING HUMAN IMMUNODEFICIENCY VIRUS AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 2, page no. ppd335-d343, February-2024, Available at : http://www.jetir.org/papers/JETIR2402343.pdf